Mark T Iwicki bought stock once, on Feb 26, 2018

Mark T. Iwicki is a seasoned biopharmaceutical executive and corporate insider who most recently traded in shares of Kala Bio, Inc. (KALA) in his capacity as Chief Executive Officer.( He served as CEO of KALA BIO from 2015 until February 2025, during which time he led the company’s evolution in ophthalmology and rare disease, and now continues to serve as Chair of Kala’s Board of Directors.( Iwicki has more than 30 years of biopharmaceutical industry experience, including multiple CEO roles and extensive board service across innovative biotech companies.(

Prior to and alongside his leadership at Kala Bio, Iwicki held senior executive positions as President and CEO of Civitas Therapeutics, Blend Therapeutics, and Sunovion Pharmaceuticals, and as President and Chief Operating Officer at Sepracor.( Earlier in his career, he served as Vice President and Business Unit Head at Novartis Pharmaceuticals and held management roles at Astra Merck and Merck & Co..( He currently serves as Chief Executive Officer of Inhibikase Therapeutics, Inc., while sitting on the boards of Nimbus, Akero Therapeutics, Third Harmonic Bio, Q32 Bio, and Merus, among others, reflecting his broad influence in the biopharmaceutical sector.( Iwicki holds a B.S. in Business Administration from Ball State University and an M.B.A. from Loyola University, underpinning his long track record in drug development, commercialization, and corporate leadership.(

Written by Perplexity from public sources.